Karsinoma Nasofaring

01Pathophysiology

Nasopharyngeal carcinoma (NPC) arises from the epithelial lining of the nasopharynx, with a strong predilection for the fossa of Rosenmuller (pharyngeal recess), a small mucosal depression located just posterior and superior to the torus tubarius. This anatomic location is critical because its proximity to several important structures explains the diverse clinical manifestations of this tumor.

EBV plays a central etiologic role, particularly in the endemic (undifferentiated) subtype. The virus infects nasopharyngeal epithelial cells and drives oncogenesis through expression of latent membrane proteins (LMP1, LMP2) and EBV nuclear antigens, which promote cell proliferation, inhibit apoptosis, and facilitate immune evasion. Elevated EBV VCA-IgA and plasma EBV DNA levels serve as both diagnostic and prognostic biomarkers.

The tumor spreads locally by invading the skull base, which gives access to the cavernous sinus and the cranial nerves traversing it. This is why patients may present with cranial nerve palsies involving CN III, IV, V (particularly V2), and VI. Lateral extension toward the parapharyngeal space can compress CN IX through XII. The tumor has a remarkable tendency for early lymphatic dissemination to retropharyngeal and upper cervical lymph nodes, which is why up to 70-80% of patients present with cervical lymphadenopathy as their initial complaint rather than primary site symptoms.

Obstruction of the Eustachian tube orifice by the tumor leads to negative middle ear pressure and subsequent serous otitis media. A unilateral middle ear effusion in an adult, particularly one from an endemic region, should always raise suspicion for NPC until proven otherwise. Posterior nasal obstruction and mucosal ulceration account for the symptoms of nasal blockage and epistaxis.

02Classification and Clinical Manifestation

WHO Histologic Classification

WHO Type III is the most common subtype overall and the most commonly tested. Despite being poorly differentiated, it paradoxically carries the best prognosis among all subtypes because it is highly radiosensitive and tends to elicit a robust immune response (reflected by its dense lymphocytic infiltrate).

Clinical Manifestation by Region of Spread

The classic clinical triad taught for NPC is: (1) cervical lymphadenopathy, (2) nasal symptoms (epistaxis/obstruction), and (3) unilateral ear complaints (serous otitis media). In practice, the neck mass is often the presenting symptom that brings the patient to medical attention.

03Diagnostic Workup

Diagnostic Summary Table

Nasal endoscopy with biopsy is the definitive diagnostic step. When a patient from an endemic background presents with a neck mass or unilateral serous otitis media, endoscopic examination of the nasopharynx is mandatory. The fossa of Rosenmuller must be carefully inspected, as early lesions can be subtle. A punch or forceps biopsy provides the tissue for histopathologic confirmation.

EBV serology is highly useful as a screening and adjunctive tool. Elevated VCA-IgA and early antigen (EA)-IgA titers are found in a large proportion of NPC patients, often preceding clinical symptoms. In endemic regions, EBV serology is used for population-level screening. However, serology alone is not confirmatory because elevated titers can be found in other EBV-related conditions.

Plasma EBV DNA quantification has become an increasingly important tool. Pre-treatment levels correlate with tumor stage and volume. A persistently elevated or rising EBV DNA level after treatment is a strong indicator of residual or recurrent disease. It is now widely used for post-treatment surveillance.

MRI is the preferred imaging modality for evaluating the primary tumor. It provides superior delineation of soft tissue extent, perineural spread, intracranial extension, and retropharyngeal lymphadenopathy compared to CT. CT remains complementary when evaluating bony destruction of the skull base. For distant staging, PET-CT is the standard for detecting metastases in bone, liver, and lungs.

One important exam point: in any adult presenting with unilateral serous otitis media without an obvious cause (such as recent upper respiratory infection), the workup must include nasopharyngeal examination to exclude NPC. Performing myringotomy alone without examining the nasopharynx is an incomplete and potentially dangerous approach.

04Management and Treatment

Management Summary Table

Radiation therapy is the backbone of NPC treatment because the tumor is exceptionally radiosensitive, particularly the undifferentiated (WHO Type III) subtype. IMRT is the current standard technique because it allows precise dose delivery to the irregularly shaped nasopharyngeal target volume while sparing adjacent critical structures such as the parotid glands, temporal lobes, brainstem, and spinal cord. This significantly reduces long-term toxicity, particularly xerostomia (dry mouth from parotid damage), which was a major complication of older radiation techniques.

For early-stage disease (T1N0), radiation therapy alone achieves excellent control rates (over 90% five-year survival), and adding chemotherapy provides no additional benefit while increasing toxicity.

For locally advanced disease, the landmark Intergroup 0099 trial established concurrent cisplatin-based chemoradiation followed by adjuvant cisplatin/5-FU as the standard of care. Cisplatin acts as a radiosensitizer, enhancing the cytotoxic effects of radiation on tumor cells. The concurrent phase typically uses cisplatin at 100 mg/m${}^2^2$ given on Days 1, 22, and 43 of the radiation course. The adjuvant phase follows with three cycles of cisplatin and 5-FU.

More recent evidence supports induction chemotherapy (gemcitabine plus cisplatin) before chemoradiation as an alternative sequencing strategy for locally advanced disease, showing improved failure-free survival in several trials.

Contraindications and adjustments: Cisplatin is nephrotoxic and ototoxic, requiring adequate hydration, monitoring of renal function, and audiometric surveillance. In patients with renal impairment, carboplatin can be substituted. Radiation to the nasopharynx commonly causes xerostomia, mucositis, dysphagia, and hypothyroidism (from incidental thyroid irradiation), all of which require proactive management.

Surgery has a very limited role in primary NPC management due to the deep anatomic location and difficulty achieving clear margins. It is reserved for salvage treatment of localized recurrences that are not amenable to re-irradiation.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students miss NPC questions is by failing to connect a unilateral serous otitis media in an adult to a nasopharyngeal malignancy. The vignette will describe a middle-aged Southeast Asian male with persistent ear fullness and conductive hearing loss, and the trap answer will be to perform myringotomy with tube insertion or to treat empirically for otitis media. The correct next step is always to examine the nasopharynx first. Any adult with unexplained unilateral middle ear effusion requires nasopharyngeal evaluation before any other intervention.

A second common trap involves the painless neck mass. The vignette may emphasize the neck mass without initially mentioning nasal or ear symptoms, tempting students toward a diagnosis of lymphoma or a branchial cleft cyst. The discriminator is the demographic (Southeast Asian descent), the posterior cervical/jugulodigastric location, and associated EBV markers. When lymphoma is offered as a distractor, remember that NPC is an epithelial tumor, not a lymphoid one, and histopathology with immunohistochemistry will differentiate the two.

Third, students often confuse NPC with juvenile nasopharyngeal angiofibroma because both involve the nasopharynx. The key distinction is patient age and sex: angiofibroma occurs in adolescent males and is vascular (biopsy is contraindicated), while NPC occurs in middle-aged adults and requires tissue biopsy for diagnosis.

Finally, remember that NPC is the head and neck cancer where radiation is the primary treatment modality, not surgery. This is the opposite of most other head and neck squamous cell carcinomas, where surgery followed by adjuvant radiation is standard. The test-writer is evaluating whether you understand that the deep nasopharyngeal location and high radiosensitivity of NPC make chemoradiation the treatment of choice, and that surgery is reserved only for recurrence salvage.